Elan Corporation PLC 2Q Loss Narrows As MS Drug Sales Grow

AP -- Losses are narrowing at Elan Corp. PLC as sales of its key drug, the multiple sclerosis-fighting Tysabri, keep growing in the United States and Europe, the Irish biopharmaceutical company reported Tuesday.

MORE ON THIS TOPIC